Cardio-Oncology


A thorough understanding of cardio-oncology is very essential for the effective treatment of cancer patients. Virtually all antineoplastic agents are related with cardio toxicity. All patients who are being considered for chemotherapy, particularly the individuals who have earlier history of heart sickness ought to experience point by point cardiovascular assessment to advance the treatment. Sequential examination of left ventricular systolic function and cardiac biomarkers might also be considered in the selected populations of patient. Cardio-toxic effects of chemotherapy can be decreased by the frequent use of angiotensin-converting inhibitors of enzyme, angiotensin receptor blockers, or beta-blockers. Antiplatelet or anticoagulation therapy may be taken in patients with a potential hyper-coagulable state related with chemotherapy or malignant growth.



 


    Related Conference of Cardio-Oncology

    October 20-21, 2026

    15th World Heart Congress

    London, UK
    November 09-10, 2026

    7th Annual Summit on Cardiology and Heart Diseases

    Paris, France
    November 16-17, 2026

    8th World Heart Congress

    Tokyo, Japan
    November 23-24, 2026

    40th World Congress on Heart Diseases

    Toronto, Canada
    November 25-26, 2026

    33rd World Heartcare Summit

    Paris, France
    January 26-27, 2027

    12th International Heart Conference

    Dubai, UAE
    March 18-19, 2027

    16th World Heart Congress

    Paris, France
    May 13-14, 2027

    10th Annual Heart Rhythm Conference

    Rome, Italy
    June 17-18, 2027

    10th World Heart and Brain Conference

    London, UK
    June 21-22, 2027

    8th European Summit on Cardiology Research

    Zurich, Switzerland

    Cardio-Oncology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in